Interim report January

The company reported Q1 net revenue of SEK 4.9 million, up from SEK 3.9 million, while EBITDA improved to SEK -1.5 million from SEK -3.7 million and operating loss narrowed to SEK -1.9 million. Cash and cash equivalents were SEK 222.5 million, down from SEK 268.9 million. A key event was regulatory approval of an additional terbinafine supplier for MOB-015/Terclara® in Australia, New Zealand, South Korea and Taiwan.

Analysis

The key second-order change is not the modest quarter itself but the reduction in supply-chain fragility: adding a second terbinafine source meaningfully lowers single-supplier risk for a product that likely needs uninterrupted availability to scale in a competitive topical antifungal market. That should improve confidence in launch continuity, reduce the probability of stock-out-driven share loss, and modestly raise the option value of the license portfolio even if near-term revenue remains small.

The market is likely underpricing the regulatory signal versus the reported P&L. In small-license pharma, the path from “one approved supplier” to “operationally resilient commercial supply” can be the difference between a product that remains a niche royalty stream and one that can support broader territory expansion or better bargaining power with distributors. The largest beneficiaries are likely the company’s commercial counterparties and ultimately patients/retail channels; the biggest losers are any single-source incumbent manufacturers or would-be generic challengers relying on supply bottlenecks to preserve pricing.

Catalyst timing matters: the approval is a days-to-weeks de-risking event, while any revenue inflection from improved supply reliability is a months-to-quarters story. The main tail risk is execution failure elsewhere in the launch stack—regulatory clearance does not fix demand generation, reimbursement friction, or inventory management. A reversal would likely come only if broader commercialization stalls or if the new supplier introduces quality issues, which would be a low-probability but high-impact event over the next 3-12 months.

Consensus may be missing that the real asset here is process optionality, not the current quarterly burn profile. If management can show a pattern of de-risking the manufacturing base, the multiple on the license portfolio can expand before revenue catches up, because investors pay for durability in specialty pharma supply more than for one quarter of EBITDA progression. The move looks underdone if the street is still valuing this as a pre-commercial cash box rather than a platform with reduced supply risk and improved scalability.

Key Decisions for Investors

• Long the name on weakness for a 3-6 month horizon: the new supplier approval is a modest but real de-risking catalyst, with asymmetric upside if the market rerates supply durability before revenue inflects.
• If there is a liquid peer basket, pair long this license-driven small-cap pharma against short a more execution-fragile specialty pharma peer with higher single-product concentration; the relative thesis is supply-chain resilience vs. operational fragility.
• Use any post-event pop to sell out-of-the-money calls or trim 25-33% of the position: the near-term catalyst is de-risking, not a step-change in earnings, so upside likely caps until commercial data improves.
• Set a 1-2 quarter checkpoint on inventory/supply disclosures; if management does not show improved product continuity or territory expansion optionality by then, fade the rerating thesis.
• Avoid shorting outright on this headline alone: the balance of risks is skewed toward incremental derisking rather than deterioration, and short carry will be unattractive unless commercialization reaccelerates.